Navigation Links
Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Third Quarter and First Nine Months of Fiscal Year 2011
Date:1/30/2011

ability of the Company's data; (x) lack of success in attaining full compliance with regard to regulatory and cGMP compliance; (xi) inability to achieve successful remediation efforts(xii) dependence on limited customer base; (xiii) occasional credits to certain customers reflecting price reductions on products previously sold to them and still available as shelf-stock; (xiv) possibility of an incorrect estimate of charge-backs and the impact of such an incorrect estimate on net sales, gross profit and net income; (xv) dependence on few products generating majority of sales; (xvi) product liability claims for which the Company may be inadequately insured; (xvii) subjectivity in judgment of management in applying certain significant accounting policies derived based on historical experience, terms of contracts, our observations of trends of industry, information received from our customers and other sources, to estimate revenues, accounts receivable allowances including chargebacks, rebates, income taxes, values of assets and inventories; (xviii) litigation involving claims of patent infringement; (xix) litigation involving claims for royalties and/or options relating to a prior contract for one product and (xx) material litigation from product recalls, (xxi) the purported class action lawsuits alleging federal securities laws violations, (xxii) delays in returning the Company's products to market, including loss of market share, and (xxiii) excessive dependency for revenues on the marketing agreement and distribution and sale agreement, both signed with Sun Pharma; (xxiv) excessive dependency on Sun Pharma and other third parties for manufacture of Caraco owned products; and (xxv) inability to successfully transfer Caraco-owned products to other manufacturing sites; (xxvi) other risks identified in this report and identified from time to time in our reports and registration statements filed with the Securities and Exchange Commission. These forward-looking statement
'/>"/>
SOURCE Caraco Pharmaceutical Laboratories, Ltd.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Caraco Pharmaceutical Laboratories, Ltd. Provides Update on Remediation Activities
2. Caraco Pharmaceutical Laboratories, Ltd. Announces Extension and Future Termination of Distribution Agreements with Sun Pharma
3. Independent Committee of Caraco Board Retains Independent Advisors for Consideration of Sun Pharma Proposal to Purchase Outstanding Shares and Caraco Acknowledges Filing of Purported Class Action Lawsuits
4. Independent Committee of Caraco Board to Consider Sun Pharma Proposal to Purchase Outstanding Shares
5. Caraco Receives Sun Pharma Proposal to Purchase All Outstanding Shares
6. Caraco Pharmaceutical Laboratories, Ltd. Reports Results for the Second Quarter and First Six Months of Fiscal Year 2011
7. Caraco Pharmaceutical Laboratories, Ltd. Announces Change to Executive Team as G. P. Singh to Assume Position of CEO Effective November 1, 2010 and Update on Remediation Status
8. Caraco Pharmaceutical Laboratories, Ltd. Announces Appointment of Eddie Munson to Board of Directors
9. Caraco Pharmaceutical Laboratories, Ltd. Announces G.P. Singh Sachdeva Is Appointed as Chief Operating Officer
10. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Flomax®
11. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Wellbutrin SR® Extended Release Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/16/2014)... Sept. 16, 2014  Wearable sports and activity ... less than two years, producing a massive amount ... huge opportunity exists for leveraging this data to ... ) introduced a first-of-its-kind wearable analytics platform for ... of clinical research linking activity and health risks, ...
(Date:9/16/2014)... Sept. 16, 2014  Relmada Therapeutics, Inc., (OTCBB: RLMD), ... of chronic pain, announced today that it has entered ... (MSKCC) in a series of animal studies for levorphanol, ... extended release form of levorphanol.  Gavril Pasternak, MD, PhD, ... Dr. Pasternak said, "Levorphanol is a ...
(Date:9/16/2014)... 2014 Henry Schein, Inc. (NASDAQ: ... health care products and services to office-based dental, ... Stanley M. Bergman, Henry Schein,s Chairman of the Board and ... services panel at the Leerink Partners Services Roundtable on Tuesday, ... Dr. Stohler, Dean of Columbia University,s College of ...
Breaking Medicine Technology:Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 2Doctors Launch Initiative to Bridge Gap Between Wearables and Meaningful Health Data 3Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 2Relmada Therapeutics Enters Into Agreement with Memorial Sloan Kettering to Better Clarify Unique Mechanism of Action for LevoCap ER 3Henry Schein To Present At The Leerink Partners Services Roundtable 2
(Date:9/16/2014)... September 16, 2014 Recently, BuyTopDress.com, one ... has unveiled its new collection of elegant graduation ... these brand new items are on sale on the ... from 23 to 63 percent off. , These ... and design. They are available in a lot of ...
(Date:9/16/2014)... CA (PRWEB) September 16, 2014 Dr. ... the launch of ACLsurgeryLA.com , a specialty website ... injuries. As an avid sports lover and athlete, ... for treatment and recovery from injuries to maintain active, ... to offer patients a resource dedicated specifically to ...
(Date:9/16/2014)... 2014 MEDICC Review today ... genetics in Cuba. Although the articles do not ... are intrinsically connected, since cancers begin with errors in ... full spectrum of cancer control, from primary prevention to ... topic of an exclusive interview with National Medical ...
(Date:9/16/2014)... (PRWEB) September 16, 2014 Lambda Solutions, a ... systems , is excited to welcome Stewart Rogers ... Harvey, Sales Executive at Lambda Solutions comments, “Product leadership will ... right candidate to do so. Learning and talent management is ... changes to help clinical learning and talent development in the ...
(Date:9/16/2014)... Birmingham, Alabama (PRWEB) September 16, 2014 *To ... Birmingham, AL, visit Achieve Clinical Research on the web ( ... For those who qualify:, There is ... required , Compensation may be provided for ... stands, pneumonia and influenza are the eighth leading cause of ...
Breaking Medicine News(10 mins):Health News:Cheap Graduation Dresses Now Provided Online At BuyTopDress.com 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 2Health News:Los Angeles Orthopedic Surgeon Spotlights ACL Conditions With New Website 3Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 2Health News:MEDICC Review Journal Dedicates Double Issue to Cancer and Genetics 3Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 2Health News:Stewart Rogers Joins Lambda Solutions as Director of Product Management 3Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 2Health News:The Team at Achieve Clinical Research is Enrolling Qualified Individuals to Participate in a Pneumonia Vaccine Clinical Trial in Birmingham, Alabama 3
... HealthDay Reporter , WEDNESDAY, Nov. 24 (HealthDay News) -- ... diagnosed until the disease is well-advanced and, therefore, less ... one-half of colorectal cancers and cervical cancers and one-third ... at a late stage, according to the report released ...
... WEDNESDAY, Nov. 24 (HealthDay News) -- A study conducted ... for blacks than it is for whites. In fact, ... one-fifth higher than it is for whites in that state. ... on Smoking and Health at the U.S. Centers for Disease ...
... London, UK, 24 November 2010 Research from ... ( http://www2.i-med.ac.at/psychlab/ ) at the Medical University Innsbruck ... in rats exhibited pathologies similar to Alzheimer,s disease. ... Neuroscience (45(4):408-417, 2010) with lead author Dr. ...
... holder of endowed chair during a research symposium at Children,s ... A. DeClerck, MD, professor of Pediatrics, Biochemistry and Molecular Biology ... Southern California has been inducted as the inaugural holder of ... "My family has long been dedicated to improving the ...
... 24 (HealthDay News) -- If you are one of the ... a few simple steps can help reduce your stress on ... School of Nursing at Binghamton University, State University of New ... items well ahead of time and have a list ready ...
... HealthDay Reporter , TUESDAY, Nov. 23 (HealthDay News) -- A ... 44 percent in those at highest risk for contracting the virus, ... finds. The reduction in risk climbed to nearly 73 percent ... of the time, the researchers added. Truvada is already available ...
Cached Medicine News:Health News:Too Many Cancers Still Spotted Too Late: CDC 2Health News:Too Many Cancers Still Spotted Too Late: CDC 3Health News:Black Smokers May Face Higher Death Risk Than Whites: CDC 2Health News:Chronic high cholesterol diet produces brain damage 2Health News:Richard Call Family Endowed Chair honors Dr. Yves DeClerck at the Saban Research Institute Symposium 2Health News:Daily Pill Lowers Odds for Infection With HIV 2Health News:Daily Pill Lowers Odds for Infection With HIV 3Health News:Daily Pill Lowers Odds for Infection With HIV 4
The ADx system uses fluorescence polarization immunoassay technology for the detection of abused drugs and toxicology assays....
Innotrac Aio! immunoanalyzers are specially designed to exploit the benefits of Innotrac Diagnostics' exclusive dry chemistry and non-enhancement time-resolved fluorometry....
... The Access immunoassay system ... access benchtop analyzer that ... assays, with panels that ... thyroid, infectious disease, blood ...
...
Medicine Products: